A20 in inflammation and autoimmunity

Trends in Immunology

Volumn 35, Issue 1, 2014, Pages 22-31

  Catrysse, Leen ^a,b   Vereecke, Lars ^a,b   Beyaert, Rudi ^a,b   van Loo, Geert ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

A20; Apoptosis; Inflammation; Nuclear factor B; Tumor necrosis factor induced protein 3; Ubiquitination

Indexed keywords

B LYMPHOCYTE RECEPTOR; BINDING PROTEIN; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CASPASE RECRUITMENT DOMAIN PROTEIN 4; CD28 ANTIGEN; CD40 ANTIGEN; CYTOKINE; DEATH RECEPTOR 4; DEATH RECEPTOR 5; I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN 1; INHIBITOR OF APOPTOSIS PROTEIN 2; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; OCCLUDIN; PATTERN RECOGNITION RECEPTOR; PROTEIN A20; RECEPTOR INTERACTING PROTEIN 1; T LYMPHOCYTE RECEPTOR; TIGHT JUNCTION PROTEIN; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; WNT PROTEIN;

ADAPTIVE IMMUNITY; ANTIVIRAL ACTIVITY; APOPTOSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BONE MARROW CELL; CARCINOGENESIS; CELL DEATH; CELL TYPE; COLON ADENOMA; DENDRITIC CELL; DERMATITIS; ENTERITIS; GENE DELETION; GENE SILENCING; GENE TARGETING; GENE TRANSFER; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HOMEOSTASIS; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOMODULATION; INFLAMMATION; INFLAMMATORY DISEASE; INFLUENZA; INNATE IMMUNITY; INTESTINE EPITHELIUM CELL; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; POLYARTHRITIS; PROTEIN FUNCTION; PSORIASIS; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; UBIQUITINATION; VACCINATION;

A20; APOPTOSIS; INFLAMMATION; NUCLEAR FACTOR-ΚB; TUMOR NECROSIS FACTOR Α-INDUCED PROTEIN 3; UBIQUITINATION;

ANIMALS; AUTOIMMUNITY; B-LYMPHOCYTES; CELL DEATH; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; ENZYME ACTIVATION; GENE TARGETING; GENETIC PREDISPOSITION TO DISEASE; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INTESTINAL MUCOSA; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MYELOID CELLS; NF-KAPPA B; NUCLEAR PROTEINS; SKIN;

EID: 84891373034     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2013.10.005     Document Type: Review

References (100)

1. Hayden M.S., Ghosh S. NF-kappaB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 2012, 26:203-234.
2. Renner F., Schmitz M.L. Autoregulatory feedback loops terminating the NF-kappaB response. Trends Biochem. Sci. 2009, 34:128-135.
3. Dixit V.M., et al. Tumor necrosis factor-alpha induction of novel gene products in human endothelial cells including a macrophage-specific chemotaxin. J. Biol. Chem. 1990, 265:2973-2978.
4. Opipari A.W., et al. The A20 cDNA induced by tumor necrosis factor alpha encodes a novel type of zinc finger protein. J. Biol. Chem. 1990, 265:14705-14708.
5. Opipari A.W., et al. The A20 zinc finger protein protects cells from tumor necrosis factor cytotoxicity. J. Biol. Chem. 1992, 267:12424-12427.
6. Beyaert R., et al. A20 and A20-binding proteins as cellular inhibitors of nuclear factor-kappa B-dependent gene expression and apoptosis. Biochem. Pharmacol. 2000, 60:1143-1151.
7. Lee E.G., et al. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 2000, 289:2350-2354.
8. Turer E.E., et al. Homeostatic MyD88-dependent signals cause lethal inflammation in the absence of A20. J. Exp. Med. 2008, 205:451-464.
9. Shao L., et al. A20 restricts wnt signaling in intestinal epithelial cells and suppresses colon carcinogenesis. PLoS ONE 2013, 8:e62223.
10. Shi C.S., Kehrl J.H. TRAF6 and A20 regulate lysine 63-linked ubiquitination of Beclin-1 to control TLR4-induced autophagy. Sci. Signal. 2010, 3:ra42.
11. Lin R., et al. Negative regulation of the retinoic acid-inducible gene I-induced antiviral state by the ubiquitin-editing protein A20. J. Biol. Chem. 2006, 281:2095-2103.
12. Saitoh T., et al. A20 is a negative regulator of IFN regulatory factor 3 signaling. J. Immunol. 2005, 174:1507-1512.
13. Iwai K. Diverse ubiquitin signaling in NF-kappaB activation. Trends Cell Biol. 2012, 22:355-364.
14. Wertz I.E., et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 2004, 430:694-699.
15. Bertrand M.J., et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol. Cell 2008, 30:689-700.
16. Hitotsumatsu O., et al. The ubiquitin-editing enzyme A20 restricts nucleotide-binding oligomerization domain containing 2-triggered signals. Immunity 2008, 28:381-390.
17. Boone D.L., et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat. Immunol. 2004, 5:1052-1060.
18. Garg A.V., et al. The deubiquitinase a20 mediates feedback inhibition of interleukin-17 receptor signaling. Sci. Signal. 2013, 6:ra44.
19. Duwel M., et al. A20 negatively regulates T cell receptor signaling to NF-kappaB by cleaving Malt1 ubiquitin chains. J. Immunol. 2009, 182:7718-7728.
20. Shembade N., et al. Inhibition of NF-kappaB signaling by A20 through disruption of ubiquitin enzyme complexes. Science 2010, 327:1135-1140.
21. Skaug B., et al. Direct, noncatalytic mechanism of IKK inhibition by A20. Mol. Cell 2011, 44:559-571.
22. Tokunaga F., et al. Specific recognition of linear polyubiquitin by A20 zinc finger 7 is involved in NF-kappaB regulation. EMBO J. 2012, 31:3856-3870.
23. Verhelst K., et al. A20 inhibits LUBAC-mediated NF-kappaB activation by binding linear polyubiquitin chains via its zinc finger 7. EMBO J. 2012, 31:3845-3855.
24. Rieser E., et al. Linear ubiquitination: a newly discovered regulator of cell signalling. Trends Biochem. Sci. 2013, 38:94-102.
25. Gerlach B., et al. Linear ubiquitination prevents inflammation and regulates immune signalling. Nature 2011, 471:591-596.
26. Damgaard R.B., et al. The ubiquitin ligase XIAP recruits LUBAC for NOD2 signaling in inflammation and innate immunity. Mol. Cell 2012, 46:746-758.
27. Komander D., Barford D. Structure of the A20 OTU domain and mechanistic insights into deubiquitination. Biochem. J. 2008, 409:77-85.
28. Lin S.C., et al. Molecular basis for the unique deubiquitinating activity of the NF-kappaB inhibitor A20. J. Mol. Biol. 2008, 376:526-540.
29. Bosanac I., et al. Ubiquitin binding to A20 ZnF4 is required for modulation of NF-kappaB signaling. Mol. Cell 2010, 40:548-557.
30. Lu T.T., et al. Dimerization and ubiquitin mediated recruitment of A20, a complex deubiquitinating enzyme. Immunity 2013, 38:896-905.
31. Kensche T., et al. Analysis of nuclear factor-kappaB (NF-kappaB) essential modulator (NEMO) binding to linear and lysine-linked ubiquitin chains and its role in the activation of NF-kappaB. J. Biol. Chem. 2012, 287:23626-23634.
32. Jin Z., et al. Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell 2009, 137:721-735.
33. Bellail A.C., et al. A20 ubiquitin ligase-mediated polyubiquitination of RIP1 inhibits caspase-8 cleavage and TRAIL-induced apoptosis in glioblastoma. Cancer Discov. 2012, 2:140-155.
34. Won M., et al. Novel anti-apoptotic mechanism of A20 through targeting ASK1 to suppress TNF-induced JNK activation. Cell Death Differ. 2010, 17:1830-1840.
35. Grey S.T., et al. A20 inhibits cytokine-induced apoptosis and nuclear factor kappaB-dependent gene activation in islets. J. Exp. Med. 1999, 190:1135-1146.
36. Kool M., et al. The ubiquitin-editing protein A20 prevents dendritic cell activation, recognition of apoptotic cells, and systemic autoimmunity. Immunity 2011, 35:82-96.
37. Tavares R.M., et al. The ubiquitin modifying enzyme A20 restricts B cell survival and prevents autoimmunity. Immunity 2010, 33:181-191.
38. Verhelst K., et al. IkappaB kinase epsilon (IKKepsilon): a therapeutic target in inflammation and cancer. Biochem. Pharmacol. 2013, 85:873-880.
39. Maelfait J., et al. A20 (Tnfaip3) deficiency in myeloid cells protects against influenza A virus infection. PLoS Pathog. 2012, 8:e1002570.
40. Parvatiyar K., et al. TAX1BP1 and A20 inhibit antiviral signaling by targeting TBK1-IKKi kinases. J. Biol. Chem. 2010, 285:14999-15009.
41. Verstrepen L., et al. Expression, biological activities and mechanisms of action of A20 (TNFAIP3). Biochem. Pharmacol. 2010, 80:2009-2020.
42. Coornaert B., et al. T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20. Nat. Immunol. 2008, 9:263-271.
43. Hutti J.E., et al. IkappaB kinase beta phosphorylates the K63 deubiquitinase A20 to cause feedback inhibition of the NF-kappaB pathway. Mol. Cell. Biol. 2007, 27:7451-7461.
44. Shrikhande G.V., et al. O-glycosylation regulates ubiquitination and degradation of the anti-inflammatory protein A20 to accelerate atherosclerosis in diabetic ApoE-null mice. PLoS ONE 2010, 5:e14240.
45. Kulathu Y., et al. Regulation of A20 and other OTU deubiquitinases by reversible oxidation. Nat. Commun. 2013, 4:1569.
46. Lee J.G., et al. Reversible inactivation of deubiquitinases by reactive oxygen species in vitro and in cells. Nat. Commun. 2013, 4:1568.
47. Heyninck K., et al. Inhibition of tumor necrosis factor-induced necrotic cell death by the zinc finger protein A20. Anticancer Res. 1999, 19:2863-2868.
48. Wagner S., et al. Ubiquitin binding mediates the NF-kappaB inhibitory potential of ABIN proteins. Oncogene 2008, 27:3739-3745.
49. Iha H., et al. Inflammatory cardiac valvulitis in TAX1BP1-deficient mice through selective NF-kappaB activation. EMBO J. 2008, 27:629-641.
50. Shembade N., et al. Essential role for TAX1BP1 in the termination of TNF-alpha-, IL-1- and LPS-mediated NF-kappaB and JNK signaling. EMBO J. 2007, 26:3910-3922.
51. Shembade N., et al. The E3 ligase Itch negatively regulates inflammatory signaling pathways by controlling the function of the ubiquitin-editing enzyme A20. Nat. Immunol. 2008, 9:254-262.
52. Shembade N., et al. The ubiquitin-editing enzyme A20 requires RNF11 to downregulate NF-kappaB signalling. EMBO J. 2009, 28:513-522.
53. Kim S.W., et al. MicroRNAs miR-125a and miR-125b constitutively activate the NF-kappaB pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20). Proc. Natl. Acad. Sci. U.S.A. 2012, 109:7865-7870.
54. Gantier M.P., et al. A miR-19 regulon that controls NF-kappaB signaling. Nuc. Acid Res. 2012, 40:8048-8058.
55. Wang C.M., et al. miR-29c targets TNFAIP3, inhibits cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 2011, 411:586-592.
56. Yaseen Balkhi M., et al. miR-29 Acts as a decoy in sarcomas to protect the tumor suppressor A20 mRNA from degradation by HuR. Sci. Signal. 2013, 6:ra63.
57. Ma A., Malynn B.A. A20: linking a complex regulator of ubiquitylation to immunity and human disease. Nat. Rev. Immunol. 2012, 12:774-785.
58. Adrianto I., et al. Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus. Nat. Genet. 2011, 43:253-258.
59. Lodolce J.P., et al. African-derived genetic polymorphisms in TNFAIP3 mediate risk for autoimmunity. J. Immunol. 2010, 184:7001-7009.
60. Musone S.L., et al. Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat. Genet. 2008, 40:1062-1064.
61. Tejasvi T., et al. TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis. J. Invest. Dermatol. 2012, 132:593-600.
62. Novak U., et al. The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood 2009, 113:4918-4921.
63. Kato M., et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 2009, 459:712-716.
64. Schmitz R., et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J. Exp. Med. 2009, 206:981-989.
65. Compagno M., et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009, 459:717-721.
66. Hjelmeland A.B., et al. Targeting A20 decreases glioma stem cell survival and tumor growth. PLoS Biol. 2010, 8:e1000319.
67. Vendrell J.A., et al. A20/TNFAIP3, a new estrogen-regulated gene that confers tamoxifen resistance in breast cancer cells. Oncogene 2007, 26:4656-4667.
68. Vereecke L., et al. Enterocyte-specific A20 deficiency sensitizes to tumor necrosis factor-induced toxicity and experimental colitis. J. Exp. Med. 2010, 207:1513-1520.
69. Hovelmeyer N., et al. A20 deficiency in B cells enhances B-cell proliferation and results in the development of autoantibodies. Eur. J. Immunol. 2011, 41:595-601.
70. Kolodziej L.E., et al. TNFAIP3 maintains intestinal barrier function and supports epithelial cell tight junctions. PLoS ONE 2011, 6:e26352.
71. Saleh M., Trinchieri G. Innate immune mechanisms of colitis and colitis-associated colorectal cancer. Nat. Rev. Immunol. 2011, 11:9-20.
72. Bavi P., et al. Clinico-pathological significance of TNF alpha-induced protein3 (TNFAIP3) in Middle Eastern colorectal carcinoma. Clin. Epigenetics 2011, 2:417-418.
73. Ungerback J., et al. Genetic variation and alterations of genes involved in NFkappaB/TNFAIP3- and NLRP3-inflammasome signaling affect susceptibility and outcome of colorectal cancer. Carcinogenesis 2012, 33:2126-2134.
74. Plenge R.M., et al. Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat. Genet. 2007, 39:1477-1482.
75. Thomson W., et al. Rheumatoid arthritis association at 6q23. Nat. Genet. 2007, 39:1431-1433.
76. Matmati M., et al. A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis. Nat. Genet. 2011, 43:908-912.
77. Mabilleau G., et al. Role of the A20-TRAF6 axis in lipopolysaccharide-mediated osteoclastogenesis. J. Biol. Chem. 2011, 286:3242-3249.
78. Hammer G.E., et al. Expression of A20 by dendritic cells preserves immune homeostasis and prevents colitis and spondyloarthritis. Nat. Immunol. 2011, 12:1184-1193.
79. Hammer G.E., Ma A. Molecular control of steady-state dendritic cell maturation and immune homeostasis. Ann. Rev. Immunol. 2013, 31:743-791.
80. Song X.T., et al. A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression. Nat. Med. 2008, 14:258-265.
81. Breckpot K., et al. Attenuated expression of A20 markedly increases the efficacy of double-stranded RNA-activated dendritic cells as an anti-cancer vaccine. J. Immunol. 2009, 182:860-870.
82. Hong B., et al. Mucosal and systemic anti-HIV immunity controlled by A20 in mouse dendritic cells. J. Clin. Invest. 2011, 121:739-751.
83. Chu Y., et al. B cells lacking the tumor suppressor TNFAIP3/A20 display impaired differentiation and hyperactivation and cause inflammation and autoimmunity in aged mice. Blood 2011, 117:2227-2236.
84. Nair R.P., et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat. Genet. 2009, 41:199-204.
85. Lippens S., et al. Keratinocyte-specific ablation of the NF-kappaB regulatory protein A20 (TNFAIP3) reveals a role in the control of epidermal homeostasis. Cell Death Differ. 2011, 18:1845-1853.
86. Yu L., et al. Neuroprotective effect of A20 on TNF-induced postischemic apoptosis. Neurochem. Res. 2006, 31:21-32.
87. Mc Guire C., et al. The ubiquitin editing enzyme A20 (TNFAIP3) is upregulated during permanent middle cerebral artery occlusion but does not influence disease outcome. Cell Death Dis. 2013, 4:e531.
88. Grey S.T., et al. Genetic engineering of a suboptimal islet graft with A20 preserves beta cell mass and function. J. Immunol. 2003, 170:6250-6256.
89. Yu L.Y., et al. Direct transfer of A20 gene into pancreas protected mice from streptozotocin-induced diabetes. Acta Pharmacol. Sin. 2004, 25:721-726.
90. Longo C.R., et al. A20 protects mice from lethal radical hepatectomy by promoting hepatocyte proliferation via a p21waf1-dependent mechanism. Hepatology 2005, 42:156-164.
91. Damrauer S.M., et al. A20 modulates lipid metabolism and energy production to promote liver regeneration. PLoS ONE 2011, 6:e17715.
92. da Silva C.G., et al. A20 promotes liver regeneration by decreasing SOCS3 expression to enhance IL-6/STAT3 proliferative signals. Hepatology 2013, 57:2014-2025.
93. Arvelo M.B., et al. A20 protects mice from D-galactosamine/lipopolysaccharide acute toxic lethal hepatitis. Hepatology 2002, 35:535-543.
94. Kang N.I., et al. A20 attenuates allergic airway inflammation in mice. J. Immunol. 2009, 183:1488-1495.
95. Patel V.I., et al. A20, a modulator of smooth muscle cell proliferation and apoptosis, prevents and induces regression of neointimal hyperplasia. FASEB J. 2006, 20:1418-1430.
96. Sun S.C. Deubiquitylation and regulation of the immune response. Nat. Rev. Immunol. 2008, 8:501-511.
97. Hu H., et al. OTUD7B controls non-canonical NF-kappaB activation through deubiquitination of TRAF3. Nature 2013, 494:371-374.
98. Keusekotten K., et al. OTULIN antagonizes lubac signaling by specifically hydrolyzing Met1-linked polyubiquitin. Cell 2013, 153:1312-1326.
99. Fiil B.K., et al. OTULIN Restricts Met1-linked ubiquitination to control innate immune signaling. Mol. Cell 2013, 50:818-830.
100. Rivkin E., et al. The linear ubiquitin-specific deubiquitinase gumby regulates angiogenesis. Nature 2013, 498:318-324.